# Deacylated Ghrelin and Beta Cell Function

> **NCT01531283** · NA · UNKNOWN · sponsor: **David Dalessio** · enrollment: 30 (estimated)

## Conditions studied

- the Diabetic Process

## Interventions

- **DRUG:** unacylated ghrelin
- **DRUG:** acyl ghrelin
- **DRUG:** combined acyl and desacyl ghrelin
- **DRUG:** saline

## Key facts

- **NCT ID:** NCT01531283
- **Lead sponsor:** David Dalessio
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2013-04
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531283, "Deacylated Ghrelin and Beta Cell Function". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01531283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*